nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—GABRB2—GABA A receptor activation—GABRA3—Graves' disease	0.0469	0.0807	CbGpPWpGaD
Zaleplon—GABRA2—GABA A receptor activation—GABRA3—Graves' disease	0.0439	0.0757	CbGpPWpGaD
Zaleplon—GABRB3—GABA A receptor activation—GABRA3—Graves' disease	0.0436	0.0752	CbGpPWpGaD
Zaleplon—GABRG2—GABA A receptor activation—GABRA3—Graves' disease	0.0429	0.0738	CbGpPWpGaD
Zaleplon—GABRA1—GABA A receptor activation—GABRA3—Graves' disease	0.0375	0.0645	CbGpPWpGaD
Zaleplon—Ageusia—Methimazole—Graves' disease	0.0346	0.0861	CcSEcCtD
Zaleplon—Ageusia—Propylthiouracil—Graves' disease	0.0294	0.0732	CcSEcCtD
Zaleplon—GABRB2—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0287	0.0494	CbGpPWpGaD
Zaleplon—GABRA2—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0269	0.0464	CbGpPWpGaD
Zaleplon—GABRB3—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0267	0.046	CbGpPWpGaD
Zaleplon—GABRG2—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0262	0.0452	CbGpPWpGaD
Zaleplon—Lymphadenopathy—Methimazole—Graves' disease	0.0238	0.0593	CcSEcCtD
Zaleplon—GABRA1—Ligand-gated ion channel transport—GABRA3—Graves' disease	0.0229	0.0395	CbGpPWpGaD
Zaleplon—Lymphadenopathy—Propylthiouracil—Graves' disease	0.0203	0.0505	CcSEcCtD
Zaleplon—Neuropathy peripheral—Methimazole—Graves' disease	0.0154	0.0382	CcSEcCtD
Zaleplon—GABRB2—GABA receptor activation—GABRA3—Graves' disease	0.0152	0.0262	CbGpPWpGaD
Zaleplon—GABRA2—GABA receptor activation—GABRA3—Graves' disease	0.0143	0.0246	CbGpPWpGaD
Zaleplon—GABRB3—GABA receptor activation—GABRA3—Graves' disease	0.0142	0.0244	CbGpPWpGaD
Zaleplon—GABRG2—GABA receptor activation—GABRA3—Graves' disease	0.0139	0.024	CbGpPWpGaD
Zaleplon—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.0131	0.0325	CcSEcCtD
Zaleplon—Alopecia—Methimazole—Graves' disease	0.0124	0.031	CcSEcCtD
Zaleplon—GABRA1—GABA receptor activation—GABRA3—Graves' disease	0.0122	0.021	CbGpPWpGaD
Zaleplon—Vertigo—Methimazole—Graves' disease	0.011	0.0274	CcSEcCtD
Zaleplon—Alopecia—Propylthiouracil—Graves' disease	0.0106	0.0263	CcSEcCtD
Zaleplon—Arthralgia—Methimazole—Graves' disease	0.0104	0.026	CcSEcCtD
Zaleplon—Myalgia—Methimazole—Graves' disease	0.0104	0.026	CcSEcCtD
Zaleplon—Dysgeusia—Propylthiouracil—Graves' disease	0.0102	0.0254	CcSEcCtD
Zaleplon—Oedema—Methimazole—Graves' disease	0.01	0.0249	CcSEcCtD
Zaleplon—Vertigo—Propylthiouracil—Graves' disease	0.00936	0.0233	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00911	0.0227	CcSEcCtD
Zaleplon—Paraesthesia—Methimazole—Graves' disease	0.00898	0.0223	CcSEcCtD
Zaleplon—Somnolence—Methimazole—Graves' disease	0.00889	0.0221	CcSEcCtD
Zaleplon—GABRB2—Orphan transporters—GABRA3—Graves' disease	0.00888	0.0153	CbGpPWpGaD
Zaleplon—Arthralgia—Propylthiouracil—Graves' disease	0.00887	0.0221	CcSEcCtD
Zaleplon—Myalgia—Propylthiouracil—Graves' disease	0.00887	0.0221	CcSEcCtD
Zaleplon—Dyspepsia—Methimazole—Graves' disease	0.0088	0.0219	CcSEcCtD
Zaleplon—Oedema—Propylthiouracil—Graves' disease	0.0085	0.0212	CcSEcCtD
Zaleplon—GABRA2—Orphan transporters—GABRA3—Graves' disease	0.00832	0.0143	CbGpPWpGaD
Zaleplon—GABRB3—Orphan transporters—GABRA3—Graves' disease	0.00827	0.0142	CbGpPWpGaD
Zaleplon—GABRG2—Orphan transporters—GABRA3—Graves' disease	0.00812	0.014	CbGpPWpGaD
Zaleplon—Urticaria—Methimazole—Graves' disease	0.00794	0.0198	CcSEcCtD
Zaleplon—Body temperature increased—Methimazole—Graves' disease	0.0079	0.0197	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00774	0.0193	CcSEcCtD
Zaleplon—Paraesthesia—Propylthiouracil—Graves' disease	0.00763	0.019	CcSEcCtD
Zaleplon—Somnolence—Propylthiouracil—Graves' disease	0.00756	0.0188	CcSEcCtD
Zaleplon—Dyspepsia—Propylthiouracil—Graves' disease	0.00748	0.0186	CcSEcCtD
Zaleplon—GABRA1—Orphan transporters—GABRA3—Graves' disease	0.0071	0.0122	CbGpPWpGaD
Zaleplon—Pruritus—Methimazole—Graves' disease	0.00707	0.0176	CcSEcCtD
Zaleplon—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.007	0.0121	CbGpPWpGaD
Zaleplon—Urticaria—Propylthiouracil—Graves' disease	0.00675	0.0168	CcSEcCtD
Zaleplon—Body temperature increased—Propylthiouracil—Graves' disease	0.00672	0.0167	CcSEcCtD
Zaleplon—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00656	0.0113	CbGpPWpGaD
Zaleplon—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00652	0.0112	CbGpPWpGaD
Zaleplon—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.0064	0.011	CbGpPWpGaD
Zaleplon—Rash—Methimazole—Graves' disease	0.0063	0.0157	CcSEcCtD
Zaleplon—Dermatitis—Methimazole—Graves' disease	0.0063	0.0157	CcSEcCtD
Zaleplon—Headache—Methimazole—Graves' disease	0.00626	0.0156	CcSEcCtD
Zaleplon—GABRB2—Ion channel transport—GABRA3—Graves' disease	0.00623	0.0107	CbGpPWpGaD
Zaleplon—Pruritus—Propylthiouracil—Graves' disease	0.00601	0.015	CcSEcCtD
Zaleplon—Nausea—Methimazole—Graves' disease	0.00594	0.0148	CcSEcCtD
Zaleplon—GABRA2—Ion channel transport—GABRA3—Graves' disease	0.00584	0.0101	CbGpPWpGaD
Zaleplon—GABRB3—Ion channel transport—GABRA3—Graves' disease	0.0058	0.00999	CbGpPWpGaD
Zaleplon—GABRG2—Ion channel transport—GABRA3—Graves' disease	0.0057	0.00981	CbGpPWpGaD
Zaleplon—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.00559	0.00964	CbGpPWpGaD
Zaleplon—Rash—Propylthiouracil—Graves' disease	0.00536	0.0133	CcSEcCtD
Zaleplon—Dermatitis—Propylthiouracil—Graves' disease	0.00535	0.0133	CcSEcCtD
Zaleplon—Headache—Propylthiouracil—Graves' disease	0.00532	0.0133	CcSEcCtD
Zaleplon—GABRB2—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00526	0.00907	CbGpPWpGaD
Zaleplon—Nausea—Propylthiouracil—Graves' disease	0.00505	0.0126	CcSEcCtD
Zaleplon—GABRA1—Ion channel transport—GABRA3—Graves' disease	0.00498	0.00858	CbGpPWpGaD
Zaleplon—GABRA2—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00493	0.0085	CbGpPWpGaD
Zaleplon—GABRB3—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.0049	0.00844	CbGpPWpGaD
Zaleplon—GABRG2—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00481	0.00829	CbGpPWpGaD
Zaleplon—GABRA1—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00421	0.00725	CbGpPWpGaD
Zaleplon—GABRB2—Neuronal System—GABRA3—Graves' disease	0.00403	0.00695	CbGpPWpGaD
Zaleplon—GABRA2—Neuronal System—GABRA3—Graves' disease	0.00378	0.00651	CbGpPWpGaD
Zaleplon—GABRB3—Neuronal System—GABRA3—Graves' disease	0.00375	0.00647	CbGpPWpGaD
Zaleplon—GABRG2—Neuronal System—GABRA3—Graves' disease	0.00369	0.00635	CbGpPWpGaD
Zaleplon—GABRA1—Neuronal System—GABRA3—Graves' disease	0.00322	0.00555	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00217	0.00373	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00203	0.0035	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00202	0.00348	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00198	0.00342	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GC—Graves' disease	0.00179	0.00308	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—GABRA3—Graves' disease	0.00173	0.00299	CbGpPWpGaD
Zaleplon—AOX1—eye—Graves' disease	0.00164	0.0907	CbGeAlD
Zaleplon—AOX1—Disease—B3GNT2—Graves' disease	0.00162	0.00279	CbGpPWpGaD
Zaleplon—TSPO—eye—Graves' disease	0.0014	0.0775	CbGeAlD
Zaleplon—AOX1—Metabolism—B3GNT2—Graves' disease	0.00135	0.00233	CbGpPWpGaD
Zaleplon—TSPO—connective tissue—Graves' disease	0.00135	0.0746	CbGeAlD
Zaleplon—GABRB3—eye—Graves' disease	0.00127	0.0703	CbGeAlD
Zaleplon—GABRG2—pituitary gland—Graves' disease	0.00123	0.068	CbGeAlD
Zaleplon—GABRB3—connective tissue—Graves' disease	0.00123	0.0678	CbGeAlD
Zaleplon—AOX1—pituitary gland—Graves' disease	0.00122	0.0673	CbGeAlD
Zaleplon—AOX1—adipose tissue—Graves' disease	0.00121	0.067	CbGeAlD
Zaleplon—GABRA2—adipose tissue—Graves' disease	0.00112	0.0618	CbGeAlD
Zaleplon—AOX1—thyroid gland—Graves' disease	0.00105	0.058	CbGeAlD
Zaleplon—TSPO—pituitary gland—Graves' disease	0.00104	0.0575	CbGeAlD
Zaleplon—TSPO—adipose tissue—Graves' disease	0.00104	0.0573	CbGeAlD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.00101	0.00174	CbGpPWpGaD
Zaleplon—GABRB3—pituitary gland—Graves' disease	0.000945	0.0522	CbGeAlD
Zaleplon—TSPO—thyroid gland—Graves' disease	0.000897	0.0496	CbGeAlD
Zaleplon—GABRB3—thyroid gland—Graves' disease	0.000815	0.045	CbGeAlD
Zaleplon—CYP3A7—Metabolism—GC—Graves' disease	0.000803	0.00138	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000731	0.00126	CbGpPWpGaD
Zaleplon—AOX1—Disease—HLA-A—Graves' disease	0.000655	0.00113	CbGpPWpGaD
Zaleplon—CYP3A5—adipose tissue—Graves' disease	0.000642	0.0355	CbGeAlD
Zaleplon—CYP3A7—Metabolism—B3GNT2—Graves' disease	0.000608	0.00105	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GC—Graves' disease	0.00058	0.001	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—B3GNT2—Graves' disease	0.00044	0.000758	CbGpPWpGaD
Zaleplon—AOX1—Disease—CD4—Graves' disease	0.000422	0.000727	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GC—Graves' disease	0.00027	0.000465	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—B3GNT2—Graves' disease	0.000204	0.000352	CbGpPWpGaD
